Selonsertib is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3±0.07.

**IC50 & Target:** pIC50: 8.3±0.07 (ASK1)

**In Vitro:** Selonsertib (GS-4997) is a clinical stage ASK1 inhibitor, which has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.[1] Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor that competes with ATP in the ASK1 catalytic kinase domain.[2]

**References:**


**Caution:** Product has not been fully validated for medical applications. For research use only.